Chronic myeloid leukemia (CML) therapy has markedly improved patient prognosis after introduction of imatinib mesylate for clinical use. However, a subset of patients develops resistance to imatinib and other tyrosine kinase inhibitors (TKIs), mainly due to point mutations in the region encoding the kinase domain of the fused BCR-ABL oncogene. To identify potential therapeutic targets in imatinib‑resistant CML cells, we derived imatinib-resistant CML-T1 human cell line clone (CML-T1/IR) by prolonged exposure to imatinib in growth media. Mutational analysis revealed that the Y235H mutation in BCR-ABL is probably the main cause of CML-T1/IR resistance to imatinib. To identify alternative therapeutic targets for selective elimination of imatinib-resistant cells, we compared the proteome profiles of CML-T1 and CML-T1/IR cells using 2-DE-MS. We identified eight differentially expressed proteins, with strongly upregulated Na+/H+ exchanger regulatory factor 1 (NHERF1) in the resistant cells, suggesting that this protein may influence cytosolic pH, Ca2+ concentration or signaling pathways such as Wnt in CML-T1/IR cells. We tested several compounds including drugs in clinical use that interfere with the aforementioned processes and tested their relative toxicity to CML-T1 and CML-T1/IR cells. Calcium channel blockers, calcium signaling antagonists and modulators of calcium homeostasis, namely thapsigargin, ionomycin, verapamil, carboxyamidotriazole and immunosuppressive drugs cyclosporine A and tacrolimus (FK-506) were selectively toxic to CML-T1/IR cells. The putative cellular targets of these compounds in CML-T1/IR cells are postulated in this study. We propose that Ca2+ homeostasis can be a potential therapeutic target in CML cells resistant to TKIs. We demonstrate that a proteomic approach may be used to characterize a TKI-resistant population of CML cells enabling future individualized treatment options for patients.

BIOCEV 1st Faculty of Medicine Charles University Prague CZ 25250 Vestec Czech Republic

Department of Genetics and Microbiology Faculty of Natural Sciences Charles University Prague CZ 12843 Prague Czech Republic

Institute of Hematology and Blood Transfusion CZ 12820 Prague 2 Czech Republic

Zobrazit více v PubMed

Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85–109. PubMed

Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079–1082. doi: 10.1126/science.2408149. PubMed DOI

Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. 2000;60:2049–2055. PubMed

Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control. 2009;16:100–107. PubMed

Waller CF. Imatinib mesylate. Recent Results Cancer Res. 2014;201:1–25. doi: 10.1007/978-3-642-54490-3_1. PubMed DOI

Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Laï JL, Philippe N, Facon T, Fenaux P, Preudhomme C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002;100:1014–1018. doi: 10.1182/blood.V100.3.1014. PubMed DOI

Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473–475. doi: 10.1182/blood-2002-05-1451. PubMed DOI

Ursan ID, Jiang R, Pickard EM, Lee TA, Ng D, Pickard AS. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: A meta-analysis of clinical trials of tyrosine kinase inhibitors. J Manag Care Spec Pharm. 2015;21:114–122. doi: 10.18553/jmcp.2015.21.2.114. PubMed DOI PMC

Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet. 2002;139:30–33. doi: 10.1016/S0165-4608(02)00615-5. PubMed DOI

Phan CL, Megat Baharuddin PJNB, Chin LP, Zakaria Z, Yegappan S, Sathar J, Tan S-M, Purushothaman V, Chang KM. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2008;180:60–64. doi: 10.1016/j.cancergencyto.2007.09.014. PubMed DOI

Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker AJ, Corey SJ. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia. 1999;13:855–861. doi: 10.1038/sj.leu.2401429. PubMed DOI

Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011;4:6. doi: 10.1186/1756-8722-4-6. PubMed DOI PMC

Petrak J, Toman O, Simonova T, Halada P, Cmejla R, Klener P, Zivny J. Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots to in vitro assays using TOP15 charts. Proteomics. 2009;9:5006–5015. doi: 10.1002/pmic.200900335. PubMed DOI

Lorkova L, Scigelova M, Arrey TN, Vit O, Pospisilova J, Doktorova E, Klanova M, Alam M, Vockova P, Maswabi B, et al. Detailed functional and proteomic characterization of fludarabine resistance in mantle cell lymphoma cells. PLoS One. 2015;10:e0135314. doi: 10.1371/journal.pone.0135314. PubMed DOI PMC

Klanova M, Soukup T, Jaksa R, Molinsky J, Lateckova L, Maswabi BCL, Prukova D, Brezinova J, Michalova K, Vockova P, et al. Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: Implications for preclinical research. Lab Invest. 2014;94:806–817. doi: 10.1038/labinvest.2014.61. PubMed DOI

Poláková KM, Polívková V, Rulcová J, Klamová H, Jurcek T, Dvoráková D, Zácková D, Pospísil Z, Mayer J, Moravcová J. Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. Exp Hematol. 2010;38:20–26. doi: 10.1016/j.exphem.2009.10.003. PubMed DOI

Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, de Benedittis C, Haferlach T, Baccarani M, Martinelli G, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141:887–899. doi: 10.1007/s00432-014-1845-6. PubMed DOI

Kiedrowski L. Cytosolic zinc release and clearance in hippocampal neurons exposed to glutamate - the role of pH and sodium. J Neurochem. 2011;117:231–243. doi: 10.1111/j.1471-4159.2011.07194.x. PubMed DOI PMC

Kinsella BT, O'Mahony DJ, Fitzgerald GA. The human thromboxane A2 receptor α isoform (TPα) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2α. J Pharmacol Exp Ther. 1997;281:957–964. PubMed

Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440–3450. PubMed

White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, et al. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. Leukemia. 2015;29:369–376. doi: 10.1038/leu.2014.217. PubMed DOI PMC

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

Kuriyama K, Gale RP, Tomonaga M, Ikeda S, Yao E, Klisak I, Whelan K, Yakir H, Ichimaru M, Sparkes RS, et al. CML-T1: A cell line derived from T-lymphocyte acute phase of chronic myelogenous leukemia. Blood. 1989;74:1381–1387. PubMed

Drexler HG. Leukemia cell lines: In vitro models for the study of chronic myeloid leukemia. Leuk Res. 1994;18:919–927. doi: 10.1016/0145-2126(94)90103-1. PubMed DOI

Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NCP, Berger U, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190–2196. doi: 10.1038/sj.leu.2402741. PubMed DOI

Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472–3475. doi: 10.1182/blood.V99.9.3472. PubMed DOI

Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, Serkova NJ. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res. 2009;15:3442–3450. doi: 10.1158/1078-0432.CCR-08-3291. PubMed DOI

Adamia S, Pilarski PM, Bar-Natan M, Stone RM, Griffin JD. Alternative splicing in chronic myeloid leukemia (CML): A novel therapeutic target? Curr Cancer Drug Targets. 2013;13:735–748. doi: 10.2174/15680096113139990083. PubMed DOI

Reczek D, Berryman M, Bretscher A. Identification of EBP50: A PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family. J Cell Biol. 1997;139:169–179. doi: 10.1083/jcb.139.1.169. PubMed DOI PMC

Ardura JA, Friedman PA. Regulation of G protein-coupled receptor function by Na+/H+ exchange regulatory factors. Pharmacol Rev. 2011;63:882–900. doi: 10.1124/pr.110.004176. PubMed DOI PMC

Li M, Wang W, Soroka CJ, Mennone A, Harry K, Weinman EJ, Boyer JL. NHERF-1 binds to Mrp2 and regulates hepatic Mrp2 expression and function. J Biol Chem. 2010;285:19299–19307. doi: 10.1074/jbc.M109.096081. PubMed DOI PMC

He P, Yun CC. Mechanisms of the regulation of the intestinal Na+/H+ exchanger NHE3. J Biomed Biotechnol. 2010;2010:238080. PubMed PMC

Obukhov AG, Nowycky MC. TRPC5 activation kinetics are modulated by the scaffolding protein ezrin/radixin/moesin-binding phosphoprotein-50 (EBP50) J Cell Physiol. 2004;201:227–235. doi: 10.1002/jcp.20057. PubMed DOI

Tang Y, Tang J, Chen Z, Trost C, Flockerzi V, Li M, Ramesh V, Zhu MX. Association of mammalian Trp4 and phospholipase C isozymes with a PDZ domain-containing protein, NHERF. J Biol Chem. 2000;275:37559–37564. doi: 10.1074/jbc.M006635200. PubMed DOI

Wheeler DS, Barrick SR, Grubisha MJ, Brufsky AM, Friedman PA, Romero G. Direct interaction between NHERF1 and Frizzled regulates β-catenin signaling. Oncogene. 2011;30:32–42. doi: 10.1038/onc.2010.389. PubMed DOI PMC

Karvar S, Suda J, Zhu L, Rockey DC. Distribution dynamics and functional importance of NHERF1 in regulation of Mrp-2 trafficking in hepatocytes. Am J Physiol Cell Physiol. 2014;307:C727–C737. doi: 10.1152/ajpcell.00011.2014. PubMed DOI

Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta. 1996;1288:F37–F54. PubMed

Canitrot Y, Lahmy S, Buquen JJ, Canitrot D, Lautier D. Functional study of multidrug resistance with fluorescent dyes. Limits of the assay for low levels of resistance and application in clinical samples. Cancer Lett. 1996;106:59–68. doi: 10.1016/0304-3835(96)04301-7. PubMed DOI

Donowitz M, Cha B, Zachos NC, Brett CL, Sharma A, Tse CM, Li X. NHERF family and NHE3 regulation. J Physiol. 2005;567:3–11. doi: 10.1113/jphysiol.2005.090399. PubMed DOI PMC

Garciarena CD, Youm JB, Swietach P, Vaughan-Jones RD. H+-activated Na+ influx in the ventricular myocyte couples Ca2+-signalling to intracellular pH. J Mol Cell Cardiol. 2013;61:51–59. doi: 10.1016/j.yjmcc.2013.04.008. PubMed DOI

Rich IN, Worthington-White D, Garden OA, Musk P. Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na+/H+ exchanger. Blood. 2000;95:1427–1434. PubMed

Pinton P, Ferrari D, Magalhães P, Schulze-Osthoff K, Di Virgilio F, Pozzan T, Rizzuto R. Reduced loading of intracellular Ca2+ stores and downregulation of capacitative Ca2+ influx in Bcl-2-overexpressing cells. J Cell Biol. 2000;148:857–862. doi: 10.1083/jcb.148.5.857. PubMed DOI PMC

Condrescu M, Opuni K, Hantash BM, Reeves JP. Cellular regulation of sodium-calcium exchange. Ann NY Acad Sci. 2002;976:214–223. doi: 10.1111/j.1749-6632.2002.tb04744.x. PubMed DOI

Iwamoto T, Watanabe Y, Kita S, Blaustein MP. Na+/Ca2+ exchange inhibitors: A new class of calcium regulators. Cardiovasc Hematol Disord Drug Targets. 2007;7:188–198. doi: 10.2174/187152907781745288. PubMed DOI

Thastrup O, Cullen PJ, Drøbak BK, Hanley MR, Dawson AP. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2+-ATPase. Proc Natl Acad Sci USA. 1990;87:2466–2470. doi: 10.1073/pnas.87.7.2466. PubMed DOI PMC

Inesi G, Hua S, Xu C, Ma H, Seth M, Prasad AM, Sumbilla C. Studies of Ca2+ ATPase (SERCA) inhibition. J Bioenerg Biomembr. 2005;37:365–368. doi: 10.1007/s10863-005-9472-1. PubMed DOI

Beeler TJ, Jona I, Martonosi A. The effect of ionomycin on calcium fluxes in sarcoplasmic reticulum vesicles and liposomes. J Biol Chem. 1979;254:6229–6231. PubMed

Triggle DJ. L-type calcium channels. Curr Pharm Des. 2006;12:443–457. doi: 10.2174/138161206775474503. PubMed DOI

Hupe DJ, Boltz R, Cohen CJ, Felix J, Ham E, Miller D, Soderman D, Van Skiver D. The inhibition of receptor-mediated and voltage-dependent calcium entry by the antiproliferative L-651,582. J Biol Chem. 1991;266:10136–10142. PubMed

Alessandro R, Fontana S, Giordano M, Corrado C, Colomba P, Flugy AM, Santoro A, Kohn EC, De Leo G. Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia. J Cell Physiol. 2008;215:111–121. doi: 10.1002/jcp.21290. PubMed DOI

Perabo FG, Wirger A, Kamp S, Lindner H, Schmidt DH, Müller SC, Kohn EC. Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2. Anticancer Res. 2004;24:2869–2877. PubMed

Guo L, Ye C, Chen W, Ye H, Zheng R, Li J, Yang H, Yu X, Zhang D. Anti-inflammatory and analgesic potency of carboxy-amidotriazole, a tumorostatic agent. J Pharmacol Exp Ther. 2008;325:10–16. doi: 10.1124/jpet.107.131888. PubMed DOI

Rovira P, Mascarell L, Truffa-Bachi P. The impact of immunosuppressive drugs on the analysis of T cell activation. Curr Med Chem. 2000;7:673–692. doi: 10.2174/0929867003374778. PubMed DOI

Maguire O, Tornatore KM, O'Loughlin KL, Venuto RC, Minderman H. Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. Cytometry A. 2013;83:1096–1104. doi: 10.1002/cyto.a.22401. PubMed DOI PMC

An SM, Ding QP, Li LS. Stem cell signaling as a target for novel drug discovery: Recent progress in the WNT and Hedgehog pathways. Acta Pharmacol Sin. 2013;34:777–783. doi: 10.1038/aps.2013.64. PubMed DOI PMC

Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 2010;18:74–87. doi: 10.1016/j.ccr.2010.04.025. PubMed DOI PMC

Krebs J, Agellon LB, Michalak M. Ca2+ homeostasis and endoplasmic reticulum (ER) stress: An integrated view of calcium signaling. Biochem Biophys Res Commun. 2015;460:114–121. doi: 10.1016/j.bbrc.2015.02.004. PubMed DOI

Bilmen JG, Wootton LL, Michelangeli F. The inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase by macrocyclic lactones and cyclosporin A. Biochem J. 2002;366:255–263. doi: 10.1042/bj20020431. PubMed DOI PMC

Chelu MG, Danila CI, Gilman CP, Hamilton SL. Regulation of ryanodine receptors by FK506 binding proteins. Trends Cardiovasc Med. 2004;14:227–234. doi: 10.1016/j.tcm.2004.06.003. PubMed DOI

Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101:2368–2373. doi: 10.1182/blood.V101.6.2368. PubMed DOI

Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006;7:861–879. doi: 10.2174/138945006777709593. PubMed DOI